Pluristem Announces Appointments of Two Directors to Board
January 06 2021 - 7:00AM
Pluristem Therapeutics Inc.
(Nasdaq:PSTI) (TASE:PSTI), a leading regenerative
medicine company developing a platform of novel biological
therapeutic products, is pleased to announce the appointment of Ms.
Maital Shemesh-Rasmussen, a global health-tech marketing
strategist, and Mr. Rami Levi, a leader in global marketing and
international governmental affairs, to its Board of Directors.
Ms. Maital Shemesh-Rasmussen brings over 20
years of diverse commercialization experience across various
industries. Driving growth in the health-tech sector, she has
specifically focused on personalized care and patient-centric,
data-driven products and value-based approaches. From 2018 to 2020,
she served as Global Head of Solution Marketing at Roche
Diagnostics Information Solutions, where she defined Roche's new
health-tech strategy, bringing to market advanced digital solutions
and commercial models that positioned Roche as a world leader in
health technology.
Key positions previously held by Ms.
Shemesh-Rasmussen include: Director of Strategic and Product
Marketing at Oracle Healthcare and Precision Medicine (2013-2016),
where she drove penetration of the informatics, analytics and
precision medicine market; Vice President of Global Marketing at
JPMorgan Chase Bank (2002-2007), where she led global marketing and
technology innovation to generate multimillion-dollar growth;
Founder & CEO of Rasmussen Communications marketing agency,
where she shaped marketing strategies and messaging for financial,
health and technology firms; a consultant for startups; and a Board
Member/Marketing Chair of Healthcare Information and Management
Systems Society Northern California. Her education includes a BA in
Behavioral Sciences, Magna Cum Laude, from Ben-Gurion University of
the Negev, studies for an MA in Political Science and Communication
at Bar-Ilan University, and the Executive Education Program in
Strategy, Finance and Computer Science at Columbia University, New
York.
Mr. Rami Levi, Founder and President of Catalyst
Group International, brings over 30 years of experience in managing
successful international projects on five continents, partnering
with world leaders, and connecting nations and industry on a global
scale. His career, spanning both the public and private sectors,
has included five diplomatic missions on behalf of the State of
Israel, as well as the founding of several successful companies. A
leading expert in international affairs, global market development,
crisis management, strategic planning and government regulatory
management, Mr. Levi has generated and managed major cross
countries agreements over the years.
As Senior Deputy General & Head of Marketing
Administration at Israel's Ministry of Tourism, Mr. Levi led
numerous international initiatives and global partnerships
involving 42 governments and world-leading conglomerates. In the
private sector, he founded Catalyst Group, working as a consultant
for governments, global law firms, banks, television networks and
multinational NGOs. Mr. Levi's holds an MA with Honors in Political
Science from The Hebrew University of Jerusalem.
Pluristem Therapeutics Executive Chairman of the
Board, Zami Aberman, said: "We are very happy to have Ms.
Shemesh-Rasmussen and Mr. Levi on our Board of Directors. Maital is
an innovation-driven global Health-Tech marketing strategist and an
inspiring thinker, who is passionate about advancing healthcare
through technology. Rami is a most impressive strategist and market
developer, with proven business acumen and extensive global
connections. Together they bring immense knowledge, experience and
networking potential across industries in the global marketplace.
We feel certain that their joint capabilities will boost our
strategic resources, business development and market penetration,
contributing significantly to the success of Pluristem's
endeavors."
About Pluristem
TherapeuticsPluristem Therapeutics Inc. is a leading
regenerative medicine company developing novel placenta-based cell
therapy product candidates. The Company has reported robust
clinical trial data in multiple indications for its patented PLX
cell product candidates and is currently conducting late stage
clinical trials in several indications. PLX cell product candidates
are believed to release a range of therapeutic proteins in response
to inflammation, muscle trauma, hematological disorders and
radiation damage. The cells are grown using the Company's
proprietary three-dimensional expansion technology and can be
administered to patients off-the-shelf, without tissue matching.
Pluristem has a strong intellectual property position; a
Company-owned and operated GMP-certified manufacturing and research
facility; strategic relationships with major research institutions;
and a seasoned management team
Safe Harbor Statement This
press release contains express or implied forward-looking
statements within the Private Securities Litigation Reform Act of
1995 and other U.S. Federal securities laws. For example, Pluristem
is using forward-looking statements when it discusses that its new
directors will enhance the Board's strategic capabilities in
preparation for future growth and commercialization endeavors.
These forward-looking statements and their implications are based
on the current expectations of the management of Pluristem only,
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology
and market requirements; Pluristem may encounter delays or
obstacles in launching and/or successfully completing its clinical
trials; Pluristem’s products may not be approved by regulatory
agencies, Pluristem’s technology may not be validated as it
progresses further and its methods may not be accepted by the
scientific community; Pluristem may be unable to retain or attract
key employees whose knowledge is essential to the development of
its products; unforeseen scientific difficulties may develop with
Pluristem’s process; Pluristem’s products may wind up being more
expensive than it anticipates; results in the laboratory may not
translate to equally good results in real clinical settings;
results of preclinical studies may not correlate with the results
of human clinical trials; Pluristem’s patents may not be
sufficient; Pluristem’s products may harm recipients; changes in
legislation may adversely impact Pluristem; inability to timely
develop and introduce new technologies, products and applications;
loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of
Pluristem to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law,
Pluristem undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. For a more detailed description of the risks
and uncertainties affecting Pluristem, reference is made to
Pluristem's reports filed from time to time with the Securities and
Exchange Commission.
Contact:Dana RubinDirector of
Investor Relations972-74-7107194danar@pluristem.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/52166deb-6ea3-4a6c-a235-94cac2bdec0d
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Apr 2023 to Apr 2024